 |
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Over 500,000 new cases of CHF are diagnosed each year. In aggregate, the American Heart Association estimates that about 5 million patients in the United States and over 15 million patients worldwide are suffering with the often debilitating symptoms of CHF. CHF is the single most frequent cause of hospitalization for people 65 and older, resulting in significant medical costs. The CHF market is in excess of $14 billion. There is no cure for CHF short of a heart transplant. Although advances in pharmacology have led to better treatment, 50% of the patients with the most advanced stage of heart failure die within a year. A majority of patients are treated with drug therapy, but device-based therapy and transplantation are currently the only alternatives for patients with advanced CHF. Heart transplants are not a feasible option for most patients (only 2,300 such transplants are performed annually) and device-based therapies carry high safety risks (e.g. thrombosis, stroke, myocardial infarction and sepsis). NanoCor's target is approximately 15 million patients with symptomatic CHF in the US and in other industrialized nations (including approximately 3 million with severe late-stage disease annually). Based on competitive price assumptions and modest market penetration NanoCor believes that Carfostin™ has the long-term potential to generate worldwide annual revenues ranging from $500 million to $1.5 billion within 5 years of launch. NanoCor has secured $500,000 in private funding and obtained significant grant proceeds from the National Institutes of Health and other sources for the conduct of large animal trials. This funding will support ongoing preclinical research, licensing, business development and partnering activities. In August 2007, Medtronic, Inc. invested $3.75 million in NanoCor. Medtronic has also agreed to invest an additional $3.75 million upon NanoCor meeting certain milestones. In connection with the investment, Medtronic acquires certain rights to exclusively license NanoCor’s therapeutic for the treatment of CHF. Our goal is to establish NanoCor as a leader in the development and commercialization of therapeutics which treat cardiovascular disease at the molecular level. The key aspects of NanoCor’s business strategy are:
|
||||
| Investors | ||||
|
|
||||
| Contact Us | ||||
|
||||
870 Martin Luther King Jr. Blvd.
NanoCor Therapeutics, Inc. is engaged in the development of novel therapeutics for the treatment of various cardiovascular diseases at the molecular level. NanoCor’s lead therapeutic is Carfostin™, an intracellular protein therapeutic for the treatment of Chronic Heart Failure (CHF). Carfostin™ is comprised of the delivery of a therapeutic gene, protein Phosphatase-1 Inhibitor-1 (I-1) with the use of Biological NanoParticles (BNPs™) and the Self-Complementary Vector Technology. This novel approach, which represents an important adjunct to existing therapies, will provide a non-invasive treatment for these patients and advance the current standard of care.